A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
Clinical trial NCT04840199 · TERMINATED
Trial details
- NCT number
- NCT04840199
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-19
- Primary completion
- 2023-11-30
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.